questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Hémoprotéines
Cytochromes
Cytochrome P-450 enzyme system
Famille-26 de cytochromes P450
Famille-26 de cytochromes P450 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Attention Deficit and Disruptive Behavior Disorders
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Famille-26 de cytochromes P450 : Questions médicales les plus fréquentes",
"headline": "Famille-26 de cytochromes P450 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Famille-26 de cytochromes P450 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-04",
"dateModified": "2025-03-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Cytochrome P-450 enzyme system",
"url": "https://questionsmedicales.fr/mesh/D003577",
"about": {
"@type": "MedicalCondition",
"name": "Cytochrome P-450 enzyme system",
"code": {
"@type": "MedicalCode",
"code": "D003577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Retinoic acid 4-hydroxylase",
"alternateName": "Retinoic Acid 4-Hydroxylase",
"url": "https://questionsmedicales.fr/mesh/D000072516",
"about": {
"@type": "MedicalCondition",
"name": "Retinoic acid 4-hydroxylase",
"code": {
"@type": "MedicalCode",
"code": "D000072516",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.422.220.453.498.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Famille-26 de cytochromes P450",
"alternateName": "Cytochrome P450 Family 26",
"code": {
"@type": "MedicalCode",
"code": "D000072500",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David R Nelson",
"url": "https://questionsmedicales.fr/author/David%20R%20Nelson",
"affiliation": {
"@type": "Organization",
"name": "Department of Microbiology, Immunology and Biochemistry, University of Tennessee, Memphis, TN 38163, USA."
}
},
{
"@type": "Person",
"name": "F Peter Guengerich",
"url": "https://questionsmedicales.fr/author/F%20Peter%20Guengerich",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146. Electronic address: f.guengerich@vanderbilt.edu."
}
},
{
"@type": "Person",
"name": "Donghak Kim",
"url": "https://questionsmedicales.fr/author/Donghak%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
},
{
"@type": "Person",
"name": "Emily E Scott",
"url": "https://questionsmedicales.fr/author/Emily%20E%20Scott",
"affiliation": {
"@type": "Organization",
"name": "Program in Biophysics, University of Michigan, Ann Arbor, Michigan 48109; Departments of Medicinal Chemistry and Pharmacology, University of Michigan, Ann Arbor, Michigan 48109. Electronic address: scottee@umich.edu."
}
},
{
"@type": "Person",
"name": "Vitchan Kim",
"url": "https://questionsmedicales.fr/author/Vitchan%20Kim",
"affiliation": {
"@type": "Organization",
"name": "Department of Biological Sciences, Konkuk University, 120 Neungdongro, Gwangjjn-Gu, Seoul, 05025 Republic of Korea."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Downregulation of peripheral luteinizing hormone rescues ovariectomy-associated cognitive deficits in APP/PS1 mice.",
"datePublished": "2023-12-31",
"url": "https://questionsmedicales.fr/article/38185053",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neurobiolaging.2023.12.007"
}
},
{
"@type": "ScholarlyArticle",
"name": "The role of SIRT3 in mediating the cognitive deficits and neuroinflammatory changes associated with a developmental animal model of schizophrenia.",
"datePublished": "2023-12-18",
"url": "https://questionsmedicales.fr/article/38122862",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pnpbp.2023.110914"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-time expression and in silico characterization of pea genes involved in salt and water-deficit stress.",
"datePublished": "2023-12-15",
"url": "https://questionsmedicales.fr/article/38099977",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11033-023-09064-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effects of Altering Three Steps of Monolignol Biosynthesis on Sorghum Responses to Stalk Pathogens and Water Deficit.",
"datePublished": "2023-12-12",
"url": "https://questionsmedicales.fr/article/37430480",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1094/PDIS-08-22-1959-RE"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential deficits in social versus monetary reinforcement learning in schizophrenia: Associations with facial emotion recognition.",
"datePublished": "2023-11-27",
"url": "https://questionsmedicales.fr/article/38010759",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1037/abn0000869"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Hémoprotéines",
"item": "https://questionsmedicales.fr/mesh/D006420"
},
{
"@type": "ListItem",
"position": 5,
"name": "Cytochromes",
"item": "https://questionsmedicales.fr/mesh/D003580"
},
{
"@type": "ListItem",
"position": 6,
"name": "Cytochrome P-450 enzyme system",
"item": "https://questionsmedicales.fr/mesh/D003577"
},
{
"@type": "ListItem",
"position": 7,
"name": "Famille-26 de cytochromes P450",
"item": "https://questionsmedicales.fr/mesh/D000072500"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Famille-26 de cytochromes P450 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Famille-26 de cytochromes P450",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Famille-26 de cytochromes P450",
"description": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?\nQuels tests sont utilisés pour évaluer l'activité des CYP26 ?\nLes symptômes cliniques aident-ils au diagnostic ?\nPeut-on utiliser l'imagerie pour le diagnostic ?\nLes antécédents médicaux sont-ils importants ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=998#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Famille-26 de cytochromes P450",
"description": "Quels sont les symptômes d'une anomalie des CYP26 ?\nLes anomalies des CYP26 causent-elles des douleurs ?\nY a-t-il des symptômes cutanés associés ?\nLes troubles de l'humeur sont-ils liés aux CYP26 ?\nLes anomalies des CYP26 affectent-elles la fertilité ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=998#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Famille-26 de cytochromes P450",
"description": "Comment prévenir les dysfonctionnements des CYP26 ?\nLes tests génétiques peuvent-ils prévenir des problèmes ?\nL'évitement de certains médicaments est-il conseillé ?\nLe suivi médical régulier est-il important ?\nLes habitudes de vie influencent-elles la santé des CYP26 ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=998#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Famille-26 de cytochromes P450",
"description": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?\nLes modifications alimentaires aident-elles ?\nDes médicaments spécifiques sont-ils utilisés ?\nLa thérapie génique est-elle une option ?\nLes traitements sont-ils personnalisés ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=998#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Famille-26 de cytochromes P450",
"description": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?\nLes anomalies des CYP26 peuvent-elles causer des maladies chroniques ?\nY a-t-il un risque accru de cancer ?\nLes complications affectent-elles la qualité de vie ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=998#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Famille-26 de cytochromes P450",
"description": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?\nL'âge influence-t-il le risque ?\nLe mode de vie joue-t-il un rôle ?\nLes facteurs environnementaux sont-ils importants ?\nLes maladies préexistantes augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000072500?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders&page=998#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des cytochromes P450 26 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de sang peuvent aider à diagnostiquer les anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité des CYP26 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques et des dosages de métabolites spécifiques sont utilisés."
}
},
{
"@type": "Question",
"name": "Les symptômes cliniques aident-ils au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme des troubles hormonaux peuvent indiquer une dysfonction."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie n'est pas couramment utilisée pour diagnostiquer les CYP26."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux sont-ils importants ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les antécédents de traitement médicamenteux peuvent influencer le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une anomalie des CYP26 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes incluent des troubles métaboliques et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 causent-elles des douleurs ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent entraîner des douleurs liées à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des éruptions cutanées peuvent survenir en raison de déséquilibres métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles de l'humeur sont-ils liés aux CYP26 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de l'humeur peuvent être liés à des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 affectent-elles la fertilité ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent affecter la fertilité en perturbant les niveaux hormonaux."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements des CYP26 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un suivi médical régulier peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Les tests génétiques peuvent-ils prévenir des problèmes ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier les risques avant l'apparition des symptômes."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments est-il conseillé ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter les médicaments connus pour interférer avec les CYP26 peut être bénéfique."
}
},
{
"@type": "Question",
"name": "Le suivi médical régulier est-il important ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter précocement les anomalies."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles la santé des CYP26 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes de vie saines peuvent améliorer la fonction des CYP26."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les dysfonctionnements des CYP26 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies hormonales et des ajustements médicamenteux."
}
},
{
"@type": "Question",
"name": "Les modifications alimentaires aident-elles ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation équilibrée peut soutenir le métabolisme hormonal."
}
},
{
"@type": "Question",
"name": "Des médicaments spécifiques sont-ils utilisés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments ciblant les déséquilibres hormonaux peuvent être prescrits."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle une option ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique est encore en recherche pour traiter les anomalies des CYP26."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les anomalies des CYP26 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des troubles métaboliques graves et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "Les anomalies des CYP26 peuvent-elles causer des maladies chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent contribuer à des maladies chroniques comme le diabète."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines anomalies peuvent augmenter le risque de cancers hormonodépendants."
}
},
{
"@type": "Question",
"name": "Les complications affectent-elles la qualité de vie ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent significativement altérer la qualité de vie."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les anomalies des CYP26 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux et l'exposition à certains médicaments."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de changements hormonaux."
}
},
{
"@type": "Question",
"name": "Le mode de vie joue-t-il un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut augmenter le risque de dysfonctionnement."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils importants ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut affecter les CYP26."
}
},
{
"@type": "Question",
"name": "Les maladies préexistantes augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies peuvent prédisposer à des anomalies des CYP26."
}
}
]
}
]
}
Alzheimer's disease (AD) is more prevalent in women than men, supposing due to the decline of estrogens in menopause, accompanied by increased gonadotropins such as luteinizing hormone (LH). We and ot...
The neuroinflammatory state may contribute to the pathogenesis of many mental disorders including schizophrenia. Nicotinamide adenine dinucleotide (NAD...
To tolerate salt and water-deficit stress, the plant adapts to the adverse environment by regulating its metabolism and expressing certain stress-induced metabolic pathways. This research analyzed the...
The experiments on salt stress and water-deficit stress were carried out within greenhouse settings under controlled environment. The saturation percentage was employed to create artificial salinity c...
Salt and water-deficit stresses trigger distinct metabolic pathways, leading to the up-regulation of specific genes and the synthesis of corresponding proteins. These findings further emphasize the co...
The drought-resilient crop sorghum (...
Despite evidence that individuals with schizophrenia (SZ) have an intact desire for social relationships, they have small social networks and report high levels of loneliness. Difficulty with reinforc...
Unilateral stroke leads to asymmetric deficits in movement performance; yet its effects on naturalistic bimanual actions, a key aspect of everyday functions, are understudied. Particularly, how natura...
Thirty-three individuals with chronic stroke (15 LCVA, 18 RCVA) and 8 neurotypical age-matched controls used both hands to lift a box fitted with force transducers under unweighted and weighted condit...
Participants with stroke, particularly the RCVA group, showed impaired scaling of grip and load force rates with the addition of weight, indicating deficits in anticipatory control. While there were n...
These results suggest that individuals with stroke, particularly those with right hemisphere damage, have impairments in anticipatory planning and interlimb coordination of symmetric cooperative biman...
Phonological difficulties have been identified as a core deficit in developmental dyslexia, yet everyday speech comprehension, which relies on phonological processing, is seemingly unaffected. This ra...
Traumatic brain injury (TBI) is an important cause of disability and death. TBI leads to multiple forms of nerve cell death including ferroptosis due to iron-dependent lipid peroxidation. Anacardic ac...
We used the Feeney free-fall impact method to construct a TBI model to investigate the effect of AA on ferroptosis caused by TBI, in which Ferrostatin-1 (Fer-1), a ferroptosis inhibitor, served as a p...
We found the intensely inhibitory effect of AA on ferroptosis, which is in parallel with the results obtained after Fer-1 treatment. In addition, AA and Fer-1 mitigated TBI-mediated tissue defects, de...
AA can reduce the neurological impairment and behavioral cognitive impairment caused by TBI through the dual effect of anti-ferroptosis and anti-inflammation....
Motor evoked potential (MEP) monitoring has been widely applied in various neurosurgical operations. This study aimed to assess the predictive value of MEP monitoring for postoperative motor deficit (...
Demographic and clinical data, MEP monitoring data, and follow-up data of 42 insular glioma patients were retrospectively reviewed, and 40 patients were finally enrolled. The value of MEP monitoring f...
Statistical analysis showed that irreversible MEP changes, but not all MEP changes, were more effective in predicting PMD. The sensitivity and specificity of irreversible MEP changes for predicting lo...
MEP monitoring has been proven to be feasible in insular glioma surgery. Irreversible MEP changes showed good performance in predicting PMD. Their absence can offer an optimistic expectation for the l...
Mutations of proline-rich transmembrane protein 2 (PRRT2) lead to dyskinetic disorders such as paroxysmal kinesigenic dyskinesia (PKD), which is characterized by attacks of involuntary movements preci...